

Technology Advisory Committee B Interests Register

Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

Publication Date: 03 April 2024

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
Kate Ren	EAG		<p>Kate provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis)</p> <p>The comparators listed in the final NICE scope8 are Pd, daratumumab monotherapy and IxaRd plus three interventions that are subject to NICE evaluation (elranatamab, ciltacabtagene autoleucel and belantamab mafodotin). None of the interventions subject to NICE evaluation have had guidance published as of the 19th of September 2023, with a decision on elranatamab anticipated in February,10 the STA of ciltacabtagene autoleucel,11 and</p>	17/01/2024	It was agreed that Kate's declaration would prevent her from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
			the manufacturers of belantamab mafodotin having appealed the NICE guidance. ¹²		
Peter Wheatley Price	TAC B Committee Member	Direct	Takeda manufacture ixazomib which is used in combination with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505). We have just successfully exited the CDF (ID1635)	12/12/2023	It was agreed that Peter's declaration would prevent him from participating in discussions on this appraisal.
Neil Rabin	Clinical Expert	Direct – Financial	Celgene (BMS). Support to attend conferences, speak at educational meetings and advisory boards. Janssen-Cilag. Support to attend conferences, speak at educational meetings and advisory boards. Takeda. Support to attend conferences and advisory boards. Sanofi. Advisory board. Menarini Stemline Oncology. Advisory board. Amgen. Advisory board.	17/01/2024	It was agreed that Neil's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
Caroline Donoghue	Patient Expert	Indirect - Financial	We have received funding from the manufacturer of the technology in the last 12 months (£48,980) In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies.	17/01/2024	It was agreed that Caroline's declaration would not prevent her from participating in discussions on this appraisal.
Nigel Spencer	Patient Expert	Indirect – Financial	We have received funding from the manufacturer of the technology in the last 12 months (£48,980) In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies.	17/01/2024	It was agreed that Nigel's declaration would not prevent him from participating in discussions on this appraisal.
Jonathan Sive	Clinical Expert	Indirect - Financial	We have received funding from the manufacturer of the technology in the last 12 months (£48,980). In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies (£298,849).	17/01/2024	It was agreed that Jonathan's declaration would not prevent him from participating in discussions on this appraisal.
Jonathan Sive	Clinical Expert	Direct - Financial	Education grant from Janssen for virtual attendance at 2023 meeting	17/01/2024	It was agreed that Jonathan's declaration would not prevent him

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
			of American Society for Haematology (£826)		from participating in discussions on this appraisal.